The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

The present invention relate to bromodomain inhibitor compounds, pharmaceutical compositions comprising the bromodomain inhibitor compounds and methods of treating a disorder responsive to fee modulation of a BET family polypeptide using the compounds and pharmaceutical compositions described. (Formula (I))

##STR00001##

The present invention relate to bromodomain inhibitor compounds, pharmaceutical compositions comprising the bromodomain inhibitor compounds and methods of treating a disorder responsive to fee modulation of a BET family polypeptide using the compounds and pharmaceutical compositions described. (Formula (I))

##STR00001##

The present disclosure provides combination therapy comprising a BET inhibitor and a protein phosphatase 2A (PP2A) activator, a B-cell lymphoma-2 (Bcl-2) inhibitor, a B-cell lymphoma-extra large (Bcl-xl) inhibitor, a casein kinase 2 (CK2) inhibitor, and/or a mediator complex subunit 1 (MED1) for cancer. The combination therapy is expected to be synergistic in treating the cancer, compared to the monotherapy. Methods for identifying a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy are also provided.

Provided are carbazole-based host compounds containing a 9-membered ring represented by Formula I

##STR00001##

where the variables are defined herein. Also provided are formulations comprising these carbazole-based hosts compounds. Further provided are OLEDs and related consumer products that utilize these carbazole-based hosts compounds.

Provided are carbazole-based host compounds containing a 9-membered ring represented by Formula I

##STR00001##

where the variables are defined herein. Also provided are formulations comprising these carbazole-based hosts compounds. Further provided are OLEDs and related consumer products that utilize these carbazole-based hosts compounds.

The present disclosure provides combination therapy comprising a BET inhibitor and a protein phosphatase 2A (PP2A) activator, a B-cell lymphoma-2 (Bcl-2) inhibitor, a B-cell lymphoma-extra large (Bcl-xl) inhibitor, a casein kinase 2 (CK2) inhibitor, and/or a mediator complex subunit 1 (MED1) for cancer. The combination therapy is expected to be synergistic in treating the cancer, compared to the monotherapy. Methods for identifying a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy are also provided.

Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases such as chronic viral infection, chronic bacterial infections, cancer, sepsis or a neurological disorder.

##STR00001##

The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.